Search

Displaying results 6051 - 6060 of 10000 in total
  1. Drug

    NV-52

    go.drugbank.com/drugs/DB05673
    Experimental

    NV-52 is an investigational synthetic flavonoid thromboxane synthase (TXS) inhibitor developed for the maintenance of remission in inflammatory bowel disease.

  2. Drug

    HGS-TR2J

    go.drugbank.com/drugs/DB05895
    Experimental

    It is developed by Human Genome Sciences, Inc and is under Phase I of clinical trial.

  3. Drug

    XL820

    go.drugbank.com/drugs/DB05146
    Investigational

    XL820 exhibits dose-dependent growth inhibition in models of breast carcinoma, gliomas and leukemia. … PDGFR), mast/stem cell growth factor receptor KIT, vascular endothelial growth factor receptor 2, and platelet-derived growth factor receptor alpha, clinically validated targets implicated in a variety of

  4. Drug

    Denibulin

    go.drugbank.com/drugs/DB05932
    Experimental

    Denibulin is a novel small molecule Vascular Disrupting Agent under development by MediciNova for treatment of solid tumor cancers.

  5. Drug

    Rolicyclidine

    go.drugbank.com/drugs/DB01549
    ExperimentalIllicit

    Because of its pharmacodynamic similarity to the drug phencyclidine (PCP), rolicyclidine was added to the Schedule I list of illegal drugs in the USA in the 1970s.

  6. Drug

    AT1391

    go.drugbank.com/drugs/DB05120
    Experimental

    AT1391 is a daily insulin skin patch designed to provide continuous basal levels of insulin for patients with diabetes.

  7. Drug

    Rexin G

    go.drugbank.com/drugs/DB16450
    Investigational

    Rexin-G is a tumor-targeted, injectable retroviral vector carrying a mutant form of the cyclin G1 gene. … It is under development by Epeius Biotechnologies for the potential treatment of metastatic cancer. It is also being investigated for preventing SARSCOV-2 viral entry.

    Synonyms: DeltaRex-G, Rexin GInternational brands: Rexin-G
  8. Drug

    EVT 302

    go.drugbank.com/drugs/DB06057
    Investigational

    EVT 302 is an orally active, potent, highly selective and reversible inhibitor of MAO-B. It is in the development for smoking cessation, and potential for disease modification in Alzheimer's disease.

  9. Drug

    Liposomal prostaglandin E1

    go.drugbank.com/drugs/DB05391
    Investigational

    The liposomal formulation of PGE-1 changes the drug’s dynamics and improve its therapeutic index in ways that PGE-1 alone could not achieve. … Liposome-encapsulated form of prostaglandin E1 (Liprostin) is known to be a potent vasodilator and platelet inhibitor as well as an anti-inflammatory and anti-thrombotic agent.

  10. Drug

    N-methylnicotinamide

    go.drugbank.com/drugs/DB08840
    Investigational

    N-methylnicotinamide is an experimental drug with no approved indication or marketed formulation. … It is a metabolite of niacinamide/nicotinamide and niacin/nicotinic acid (vitamin B3), and as such N-methylnicotinamide is used to diagnose niacin deficiency by measuring N-methylnicotinamide in the urine